Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR Newswire SUNNYVALE, Calif., Nov. 12, 2024 Company reports record revenue of $1.7 million in...
WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO PR Newswire SUNNYVALE, Calif., Nov. 7, 2024...
WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT PR Newswire SUNNYVALE, Calif., Sept...
WILLOW ANNOUNCES COMMERCIAL LICENSE AND ROYALTY AGREEMENT WITH KALSEC INC. PR Newswire SUNNYVALE, Calif., Sept. 5, 2024 The agreement with Kalsec anticipates milestone payments for finalizing...
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR Newswire SUNNYVALE, Calif., Aug. 12, 2024 Company reports record revenue of $1.0 million, an...
WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY PR Newswire SUNNYVALE, Calif., Aug. 7, 2024 After a...
WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM PR Newswire SUNNYVALE, Calif., June 26, 2024 Company announced multi-product development and...
WILLOW ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS FOR MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS PR Newswire SUNNYVALE, Calif., May 30, 2024 Collaboration...
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR Newswire SUNNYVALE, Calif., May 13, 2024 Company continues to advance its corticosteroid...
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF PR Newswire SUNNYVALE, Calif., March 28, 2024 Completed the reorganization of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.01 | -11.1111111111 | 0.09 | 0.095 | 0.075 | 286094 | 0.08023551 | CS |
| 4 | -0.015 | -15.7894736842 | 0.095 | 0.1 | 0.075 | 117275 | 0.08378252 | CS |
| 12 | -0.015 | -15.7894736842 | 0.095 | 0.105 | 0.075 | 76592 | 0.08940588 | CS |
| 26 | -0.005 | -5.88235294118 | 0.085 | 0.145 | 0.075 | 94326 | 0.09813761 | CS |
| 52 | 0.01 | 14.2857142857 | 0.07 | 0.15 | 0.07 | 82883 | 0.10041499 | CS |
| 156 | -0.42 | -84 | 0.5 | 0.5 | 0.06 | 97451 | 0.15411851 | CS |
| 260 | -0.52 | -86.6666666667 | 0.6 | 2.24 | 0.06 | 151015 | 0.62263351 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
